

# Secondary Progressive Multiple Sclerosis Drug-China Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/SA8995E625AMEN.html>

Date: May 2018

Pages: 139

Price: US\$ 2,980.00 (Single User License)

ID: SA8995E625AMEN

## Abstracts

### Report Summary

Secondary Progressive Multiple Sclerosis Drug-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Secondary Progressive Multiple Sclerosis Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Secondary Progressive Multiple Sclerosis Drug 2013-2017, and development forecast 2018-2023

Main market players of Secondary Progressive Multiple Sclerosis Drug in China, with company and product introduction, position in the Secondary Progressive Multiple Sclerosis Drug market

Market status and development trend of Secondary Progressive Multiple Sclerosis Drug by types and applications

Cost and profit status of Secondary Progressive Multiple Sclerosis Drug, and marketing status

Market growth drivers and challenges

The report segments the China Secondary Progressive Multiple Sclerosis Drug market as:

China Secondary Progressive Multiple Sclerosis Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North China  
Northeast China  
East China  
Central & South China  
Southwest China  
Northwest China

China Secondary Progressive Multiple Sclerosis Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Inebilizumab  
GLX-1112  
DC-TAB  
Etomoxir  
IB-MS  
Others

China Secondary Progressive Multiple Sclerosis Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Clinic  
Others

China Secondary Progressive Multiple Sclerosis Drug Market: Players Segment Analysis (Company and Product introduction, Secondary Progressive Multiple Sclerosis Drug Sales Volume, Revenue, Price and Gross Margin):

AB Science SA  
Actelion Ltd  
Biogen, Inc.  
F. Hoffmann-La Roche Ltd.  
Genzyme Corporation  
GliaLogix, Inc.  
Immune Response BioPharma, Inc.  
Innate Immunotherapeutics Ltd

Kyorin Pharmaceutical Co., Ltd.  
Mallinckrodt Plc  
MedDay SA  
MedImmune, LLC  
Merck KGaA  
Meta-IQ ApS  
Novartis AG  
Opexa Therapeutics, Inc.  
Xenetic Biosciences (UK) Limited

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG**

- 1.1 Definition of Secondary Progressive Multiple Sclerosis Drug in This Report
- 1.2 Commercial Types of Secondary Progressive Multiple Sclerosis Drug
  - 1.2.1 Inebilizumab
  - 1.2.2 GLX-1112
  - 1.2.3 DC-TAB
  - 1.2.4 Etomoxir
  - 1.2.5 IB-MS
  - 1.2.6 Others
- 1.3 Downstream Application of Secondary Progressive Multiple Sclerosis Drug
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Others
- 1.4 Development History of Secondary Progressive Multiple Sclerosis Drug
- 1.5 Market Status and Trend of Secondary Progressive Multiple Sclerosis Drug 2013-2023
  - 1.5.1 India Secondary Progressive Multiple Sclerosis Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Secondary Progressive Multiple Sclerosis Drug Market Status and Trend 2013-2023

### **CHAPTER 2 INDIA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Secondary Progressive Multiple Sclerosis Drug in India 2013-2017
- 2.2 Consumption Market of Secondary Progressive Multiple Sclerosis Drug in India by Regions
  - 2.2.1 Consumption Volume of Secondary Progressive Multiple Sclerosis Drug in India by Regions
  - 2.2.2 Revenue of Secondary Progressive Multiple Sclerosis Drug in India by Regions
- 2.3 Market Analysis of Secondary Progressive Multiple Sclerosis Drug in India by Regions
  - 2.3.1 Market Analysis of Secondary Progressive Multiple Sclerosis Drug in North India 2013-2017
  - 2.3.2 Market Analysis of Secondary Progressive Multiple Sclerosis Drug in Northeast India 2013-2017

2.3.3 Market Analysis of Secondary Progressive Multiple Sclerosis Drug in East India 2013-2017

2.3.4 Market Analysis of Secondary Progressive Multiple Sclerosis Drug in South India 2013-2017

2.3.5 Market Analysis of Secondary Progressive Multiple Sclerosis Drug in West India 2013-2017

2.4 Market Development Forecast of Secondary Progressive Multiple Sclerosis Drug in India 2017-2023

2.4.1 Market Development Forecast of Secondary Progressive Multiple Sclerosis Drug in India 2017-2023

2.4.2 Market Development Forecast of Secondary Progressive Multiple Sclerosis Drug by Regions 2017-2023

## **CHAPTER 3 INDIA MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole India Market Status by Types

3.1.1 Consumption Volume of Secondary Progressive Multiple Sclerosis Drug in India by Types

3.1.2 Revenue of Secondary Progressive Multiple Sclerosis Drug in India by Types

3.2 India Market Status by Types in Major Countries

3.2.1 Market Status by Types in North India

3.2.2 Market Status by Types in Northeast India

3.2.3 Market Status by Types in East India

3.2.4 Market Status by Types in South India

3.2.5 Market Status by Types in West India

3.3 Market Forecast of Secondary Progressive Multiple Sclerosis Drug in India by Types

## **CHAPTER 4 INDIA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Secondary Progressive Multiple Sclerosis Drug in India by Downstream Industry

4.2 Demand Volume of Secondary Progressive Multiple Sclerosis Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Secondary Progressive Multiple Sclerosis Drug by Downstream Industry in North India

4.2.2 Demand Volume of Secondary Progressive Multiple Sclerosis Drug by Downstream Industry in Northeast India

4.2.3 Demand Volume of Secondary Progressive Multiple Sclerosis Drug by

Downstream Industry in East India

4.2.4 Demand Volume of Secondary Progressive Multiple Sclerosis Drug by  
Downstream Industry in South India

4.2.5 Demand Volume of Secondary Progressive Multiple Sclerosis Drug by  
Downstream Industry in West India

4.3 Market Forecast of Secondary Progressive Multiple Sclerosis Drug in India by  
Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG**

5.1 India Economy Situation and Trend Overview

5.2 Secondary Progressive Multiple Sclerosis Drug Downstream Industry Situation and  
Trend Overview

## **CHAPTER 6 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN INDIA**

6.1 Sales Volume of Secondary Progressive Multiple Sclerosis Drug in India by Major  
Players

6.2 Revenue of Secondary Progressive Multiple Sclerosis Drug in India by Major  
Players

6.3 Basic Information of Secondary Progressive Multiple Sclerosis Drug by Major  
Players

6.3.1 Headquarters Location and Established Time of Secondary Progressive Multiple  
Sclerosis Drug Major Players

6.3.2 Employees and Revenue Level of Secondary Progressive Multiple Sclerosis  
Drug Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 AB Science SA

7.1.1 Company profile

7.1.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.1.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of AB Science SA

7.2 Actelion Ltd

7.2.1 Company profile

7.2.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.2.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Actelion Ltd

7.3 Biogen, Inc.

7.3.1 Company profile

7.3.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.3.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Biogen, Inc.

7.4 F. Hoffmann-La Roche Ltd.

7.4.1 Company profile

7.4.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.4.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.

7.5 Genzyme Corporation

7.5.1 Company profile

7.5.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.5.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Genzyme Corporation

7.6 Glialogix, Inc.

7.6.1 Company profile

7.6.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.6.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Glialogix, Inc.

7.7 Immune Response BioPharma, Inc.

7.7.1 Company profile

7.7.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.7.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Immune Response BioPharma, Inc.

7.8 Innate Immunotherapeutics Ltd

7.8.1 Company profile

7.8.2 Representative Secondary Progressive Multiple Sclerosis Drug Product

7.8.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Innate Immunotherapeutics Ltd

7.9 Kyorin Pharmaceutical Co., Ltd.

7.9.1 Company profile

- 7.9.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
- 7.9.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Kyorin Pharmaceutical Co., Ltd.
- 7.10 Mallinckrodt Plc
  - 7.10.1 Company profile
  - 7.10.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
  - 7.10.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Mallinckrodt Plc
- 7.11 MedDay SA
  - 7.11.1 Company profile
  - 7.11.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
  - 7.11.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of MedDay SA
- 7.12 MedImmune, LLC
  - 7.12.1 Company profile
  - 7.12.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
  - 7.12.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of MedImmune, LLC
- 7.13 Merck KGaA
  - 7.13.1 Company profile
  - 7.13.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
  - 7.13.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Merck KGaA
- 7.14 Meta-IQ ApS
  - 7.14.1 Company profile
  - 7.14.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
  - 7.14.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Meta-IQ ApS
- 7.15 Novartis AG
  - 7.15.1 Company profile
  - 7.15.2 Representative Secondary Progressive Multiple Sclerosis Drug Product
  - 7.15.3 Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin of Novartis AG
- 7.16 Opexa Therapeutics, Inc.
- 7.17 Xenetic Biosciences (UK) Limited

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG**



- 8.1 Industry Chain of Secondary Progressive Multiple Sclerosis Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG**

- 9.1 Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug
- 9.2 Raw Materials Cost Analysis of Secondary Progressive Multiple Sclerosis Drug
- 9.3 Labor Cost Analysis of Secondary Progressive Multiple Sclerosis Drug
- 9.4 Manufacturing Expenses Analysis of Secondary Progressive Multiple Sclerosis Drug

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Secondary Progressive Multiple Sclerosis Drug-China Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/SA8995E625AMEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SA8995E625AMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

